Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Key Points. Patients treated with next generation BTKi therapy acalabrutinib still see a >8 fold risk of ventricular arrhythmia and sudden death events.Ventr

  • 123456 Profile photo of Madelyn

    Similar to ibrutinib before it, there is increasing awareness of the risk of ventricular arrhythmias with acalabrutinib. In a cohort of 290 consecutively treated patients there was a 8.2 increased relative risk of developing a VA compared to non-BTKi treated patients. We will need more long term f/u as acala becomes more popular.